ProgramsView all programs
From the news
- Chancellor Amma Addresses the Parliament of World’s Religions
- Amrita Students Qualify for the European Mars Rover Challenge
Publication Type : Journal Article
Publisher : Clinical and Translational Oncology (Article in Press)
Source : Clinical and Translational Oncology, 2017, Article in Press, DOI: 10.1007/s12094-021-02707-5
Keywords : Antibody; Antibody–drug conjugates; CD 147; CD 24; Cytotoxic payload; Glypican 3; Hepatocellular carcinoma; Linker; c-Met.
Campus : Kochi
School : School of Pharmacy
Department : Pharmacognosy
Year : 2021
Abstract : An antibody-drug conjugate (ADC) is an advanced chemotherapeutic option with immense promises in treating many tumor. They are designed to selectively attack and kill neoplastic cells with minimal toxicity to normal tissues. ADCs are complex engineered immunoconjugates that comprise a monoclonal antibody for site-directed delivery and cytotoxic payload for targeted destruction of malignant cells. Therefore, it enables the reduction of off-target toxicities and enhances the therapeutic index of the drug. Hepatocellular carcinoma (HCC) is a solid tumor that shows high heterogeneity of molecular phenotypes and is considered the second most common cause of cancer-related death. Studies show enormous potential for ADCs targeting GPC3 and CD24 and other tumor-associated antigens in HCC with their high, selective expression and show potential outputs in preclinical evaluations. The review mainly highlights the preclinical evaluation of different antigen-targeted ADCs such as MetFab-DOX, Anti-c-Met IgG-OXA, Anti CD 24, ANC-HN-01, G7mab-DOX, hYP7-DCand hYP7-PC, Anti-CD147 ILs-DOX and AC133-vcMMAF against hepatocellular carcinoma and its future relevance.
Cite this Research Publication : Murali, M., Kumar, A.R., Nair, B., Pradeep, G.K., Nath, L.R. Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance Clinical and Translational Oncology, 2017, DOI: 10.1007/s12094-021-02707-5 (Article in Press)